← Back to screener

Caris Life Sciences, Inc. CAI

Rank #2059 · Nasdaq · $9.7B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
35.0
P/E
-28.4
P/B
-5.70
ROE
20.1%
Op. Margin
-104.4%
Debt Ratio
-36%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -28.4x, P/B -5.70x. Ranks in the top 88% of the universe.

Profitability ★★☆☆☆
Average

ROE 20.1%. Ranks in the top 56% of the universe.

Safety ★★★★★
Excellent

Debt ratio -36%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2025$0.3B$-0.3B$-0.3B$-1.7B-104.4-36

← See the full screener